Outcomes from an Expanded Targeted Early Cytomegalovirus Testing ProgramFunding None.
11 November 2019
29 February 2020
16 April 2020 (online)
Objective This study aimed to determine the outcomes from an expanded targeted early congenital cytomegalovirus (cCMV) testing program.
Study Design A retrospective analysis of data was collected from June 2016 to April 2018 of patients who underwent expanded targeted early cCMV testing during the peri-implementation phase. Information regarding patient presentation, test type/result, and audiologic outcomes were collected. Chi-square and two-sample t-tests were performed.
Results A total of 754 patients underwent cCMV testing; during that period there were 56,947 births at 20 different hospitals. Reasons for completing cCMV testing included the following: (1) failed hearing screening (35.8%), (2) intrauterine growth restriction (IUGR) or small for gestational age (SGA) (29.1%), (3) sepsis (10.7%), (4) other/unknown (8.7%), (5) elevated liver enzymes or bilirubin (5.1%), (6) thrombocytopenia (5.1%), (7) central nervous system abnormalities (3.3%), and (8) mother with suspected cCMV infection (2.2%). The most frequent type of cCMV test performed was urine polymerase chain reaction (75.8%). A total of 21 (2.8%) patients tested positive for cCMV, of which 12 (57%) were symptomatic. This value represents a prevalence of 36.9 cCMV cases and 21.1 symptomatic cCMV cases diagnosed per 100,000 live births. Criteria most commonly associated with a positive testing were failed hearing screening (33.3%), IUGR/SGA (28.6%), and a mother with suspected cCMV infection (19.0%).
Conclusion Implementation of an expanded targeted early CMV testing program has the potential to identify symptomatic cCMV infants who would not be identified otherwise.
This article was presented as a poster at the 2019 AAO-HNSF Annual Meeting and OTO Experience in New Orleans, Louisiana, September 15 to 18, 2019. It was also declared as the Winner of Best Pediatric Otolaryngology Poster.
- 1 Kenneson A, Cannon MJ. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev Med Virol 2007; 17 (04) 253-276
- 2 Bartlett AW, McMullan B, Rawlinson WD, Palasanthiran P. Hearing and neurodevelopmental outcomes for children with asymptomatic congenital cytomegalovirus infection: a systematic review. Rev Med Virol 2017; 27: 1-10
- 3 Dollard SC, Grosse SD, Ross DS. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007; 17 (05) 355-363
- 4 Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992; 326 (10) 663-667
- 5 Boppana SB, Pass RF, Britt WJ, Stagno S, Alford CA. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J 1992; 11 (02) 93-99
- 6 Vaudry W, Lee BE, Rosychuk RJ. Congenital cytomegalovirus infection in Canada: active surveillance for cases diagnosed by paediatricians. Paediatr Child Health 2014; 19 (01) e1-e5
- 7 Townsend CL, Peckham CS, Tookey PA. Surveillance of congenital cytomegalovirus in the UK and Ireland. Arch Dis Child Fetal Neonatal Ed 2011; 96 (06) F398-F403
- 8 McMullan BJ, Palasanthiran P, Jones CA. , et al. Congenital cytomegalovirus—time to diagnosis, management and clinical sequelae in Australia: opportunities for earlier identification. Med J Aust 2011; 194 (12) 625-629
- 9 Sorichetti B, Goshen O, Pauwels J. , et al. Symptomatic congenital cytomegalovirus infection is underdiagnosed in British Columbia. J Pediatr 2016; 169: 316-317
- 10 Kimberlin DW, Jester PM, Sánchez PJ. , et al; National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med 2015; 372 (10) 933-943
- 11 James SH, Kimberlin DW. Advances in the prevention and treatment of congenital cytomegalovirus infection. Curr Opin Pediatr 2016; 28 (01) 81-85
- 12 Bale Jr JF. Screening newborns for congenital cytomegalovirus infection. JAMA 2010; 303 (14) 1425-1426
- 13 Stehel EK, Shoup AG, Owen KE. , et al. Newborn hearing screening and detection of congenital cytomegalovirus infection. Pediatrics 2008; 121 (05) 970-975
- 14 Diener ML, Zick CD, McVicar SB, Boettger J, Park AH. Outcomes from a hearing-targeted cytomegalovirus screening program. Pediatrics 2017; 139 (02) 139
- 15 Boppana SB, Ross SA, Novak Z. , et al; National Institute on Deafness and Other Communication Disorders CMV and Hearing Multicenter Screening (CHIMES) Study. Dried blood spot real-time polymerase chain reaction assays to screen newborns for congenital cytomegalovirus infection. JAMA 2010; 303 (14) 1375-1382
- 16 Gantt S, Dionne F, Kozak FK. , et al. Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection. JAMA Pediatr 2016; 170 (12) 1173-1180
- 17 Picone O, Teissier N, Cordier AG. , et al. Detailed in utero ultrasound description of 30 cases of congenital cytomegalovirus infection. Prenat Diagn 2014; 34 (06) 518-524
- 18 Hughes BL, Gyamfi-Bannerman C. ; Society for Maternal-Fetal Medicine (SMFM). Diagnosis and antenatal management of congenital cytomegalovirus infection. Am J Obstet Gynecol 2016; 214 (06) B5-B11
- 19 Grose C, Itani O, Weiner CP. Prenatal diagnosis of fetal infection: advances from amniocentesis to cordocentesis—congenital toxoplasmosis, rubella, cytomegalovirus, varicella virus, parvovirus and human immunodeficiency virus. Pediatr Infect Dis J 1989; 8 (07) 459-468
- 20 Ross SA, Boppana SB. Congenital cytomegalovirus infection: outcome and diagnosis. Semin Pediatr Infect Dis 2005; 16 (01) 44-49